trial to evaluate eprenetapopt-azacytidine combo in tp53 mds completes enrollment
Published 4 years ago • 170 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:36
eprenetapopt plus venetoclax and azacitidine in the treatment of tp53-mutated aml
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
1:57
dr. cluzeau on the efficacy of apr-246/azacitidine in tp53-mutated mds and aml
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
1:56
dr. pemmaraju on the challenges of targeting tp53 mutations in mds/aml
-
1:25
phase ii trial of eprenetapopt plus azacitidine: long-term follow up
-
7:05
combining the novel anti-cd47 antibody magrolimab with azacitidine in patients with tp53-mutant aml
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
2:38
the boven trial: mrd-guided obinutuzumab, zanubrutinib and venetoclax regimen in tp53-mutated mcl
-
20:18
case study 2: a patient with a myeloid neoplasm and a tp53 mutation
-
3:00
apr-246 in tp53 mutated mds and aml
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
1:48
tp53-mutant aml linked to poorer outcomes with decitabine plus venetoclax
-
3:34
abacus trial: preoperative atezolizumab in urothelial carcinoma
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
1:23
immunological impact of tp53 in mds
-
1:27
tp53-aberrant mcl: challenges and treatment approaches
-
0:47
what is an antigen escape?